logo-loader

OncoResponse secures investment from Baxalta

Published: 09:39 26 May 2016 EDT

Graphic of antibodies
The group’s technology rapidly screens antibodies made by the human immune system

Cancer immunotherapy specialist OncoResponse (NYSE:BXLT) has secured investment from biopharmaceutical giant Baxalta Inc, bringing the total Series A financing to US$12.5mln.

The funding will be used to support OncoResponse’s on-going research into cancer immunotherapy to identify antibodies and potential targets for novel therapeutic development.

Other backers include ARCH Venture Partners, Canaan Partners and MD Anderson, with William Marsh Rice University and Alexandria Real Estate Equities also participating

The group’s technology rapidly screens antibodies made by the human immune system to identify those indicating cancer.

“This additional investment reinforces our continued commitment to the identification of rare cancer-fighting antibodies and novel targets that may lead to the development of improved cancer treatments,” said Clifford Stocks, CEO of OncoResponse.

“[OncoResponse’s] innovative approach is in line with Baxalta’s investment strategy to accelerate the development of cutting-edge biotechnologies that address unmet patient needs,” said Geeta Vemuri, managing venture partner at Baxalta.

Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for...

Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share news the company had a successful 2023, with a final tally of 164 million USD, which is at the upper end of their forecast. The company concluded the year with 72 million USD in cash, surpassing their initial projections...

10 hours, 9 minutes ago